RT info:eu-repo/semantics/article
T1 Biological Predictors of Chemotherapy Induced Peripheral Neuropathy (CPIN): MASCC Neurological Complications Working Group Overview. Support care Cancer
A1 Morales González, Manuel José
A1 Chan, Alexandre
A1 Hertz, Daniel L.
A1 Adams, Elizabeth J.
A1 Gordon, Sharon
A1 Chia, Jie Tan
A1 Staf, Nathan P.
A1 Kamath, Jayesh
A1 Jeong, Oh
A1 Shinde, Shivani
A1 Pon, Doreen
A1 Dixit, Niharkia
A1 D’Olimpio, James
A1 Dumitrescu, Cristina
A1 Gobbo, Margherita
A1 Kober, Kord
A1 Mayo, Samantha
A1 Pang, Linda
A1 Subbiah, Ishwaria
A1 Beutler, Andreas S.
A1 Peters, Katherine B.
A1 Loprinzi, Charles
A1 Lustberg, Maryam B.
A2 Medicina InternaDermatología y Psiquiatría
K1 chemotherapy-induced peripheral neuropathy
K1 CIPN
K1 neuropathy
AB Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating conditionassociated with a number of chemotherapeutic agents. Drugs commonly implicated indevelopment of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, andthalidomide analogues. As response to the same drug can vary between individuals, it ishypothesized that an individual’s specific genetic variants could impact regulation of genesinvolved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, whichin turn affect CIPN development and severity. Variations of other molecular markers may alsoaffect the incidence and severity of CIPN. Hence, the objective of this review is to summarize theknown biological (molecular and genomic) predictors of CIPN and discuss means to facilitateprogress in this field.
YR 2019
FD 2019
LK http://riull.ull.es/xmlui/handle/915/40047
UL http://riull.ull.es/xmlui/handle/915/40047
LA en
DS Repositorio institucional de la Universidad de La Laguna
RD 21-nov-2024